Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

NCT04093505 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

28

Enrollment

OTHER

Sponsor class

Stopped Study turned out no longer feasible. End of Recruitment: 25.5.2022

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Gemtuzumab Ozogamicin 147
DRUG: Gemtuzumab Ozogamicin 1
DRUG: Glasdegib
DRUG: Placebo Oral Tablet

Sponsor

University Hospital Heidelberg